Compare PPCB & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PPCB | HSCS |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.1M | 15.8M |
| IPO Year | 2011 | 2022 |
| Metric | PPCB | HSCS |
|---|---|---|
| Price | $1.65 | $2.25 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 125.5K | 88.1K |
| Earning Date | 11-24-2026 | 12-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.84 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $4,319.00 |
| Revenue This Year | N/A | $295.93 |
| Revenue Next Year | N/A | $18,321.05 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.06 | $1.63 |
| 52 Week High | $6.79 | $5.25 |
| Indicator | PPCB | HSCS |
|---|---|---|
| Relative Strength Index (RSI) | 64.85 | 34.33 |
| Support Level | $1.23 | $1.84 |
| Resistance Level | $1.98 | $2.76 |
| Average True Range (ATR) | 0.22 | 0.35 |
| MACD | 0.02 | -0.08 |
| Stochastic Oscillator | 58.65 | 15.92 |
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare setting, either via the MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via the MyoVista wavECG Device.